AC Immune SA ACIU:NASDAQ

RT Quote | NASDAQ | USD
Last | 05/12/21 EDT
6.27quote price arrow up+0.10 (+1.62%)
Volume
131,251
52 week range
4.42 - 13.00

...

Loading . . .
  • Open6.09
  • Day High6.34
  • Day Low6.05
  • Prev Close6.27
  • 52 Week High13.00
  • 52 Week High Date07/16/20
  • 52 Week Low4.42
  • 52 Week Low Date11/02/20

Key Stats

  • Market Cap455.52M
  • Shares Out72.65M
  • 10 Day Average Volume0.17M
  • Dividend-
  • Dividend Yield-
  • Beta0.76
  • YTD % Change21.28

KEY STATS

  • Open6.09
  • Day High6.34
  • Day Low6.05
  • Prev Close6.27
  • 52 Week High13.00
  • 52 Week High Date07/16/20
  • 52 Week Low4.42
  • 52 Week Low Date11/02/20
  • Market Cap455.52M
  • Shares Out72.65M
  • 10 Day Average Volume0.17M
  • Dividend-
  • Dividend Yield-
  • Beta0.76
  • YTD % Change21.28

RATIOS/PROFITABILITY

  • EPS (TTM)-1.04
  • P/E (TTM)-6.00
  • Fwd P/E (NTM)-11.13
  • EBITDA (MRQ)-77.146M
  • ROE (MRQ)-30.01%
  • Revenue (MRQ)3.70M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-2,121.55%
  • Debt To Equity (MRQ)1.04%

EVENTS

  • Earnings Date08/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On AC Immune SA

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative...
Douglas Williams Ph.D.
Non-Executive Chairman
Andrea Pfeifer Ph.D.
Chief Executive Officer
Piergiorgio Donati
Chief Operating Officer
Joerg Hornstein
Chief Financial Officer
Address
EPFL Innovation Park, Building B
Lausanne
1015
Switzerland

Top Peers

SYMBOLLASTCHG%CHG
KALV
Kalvista Pharmaceuticals Inc
24.81-0.60-2.36%
PRVB
Provention Bio Inc
6.80-0.08-1.16%
PLSE
Pulse Biosciences Inc
19.03+1.06+5.90%
FBRX
Forte Biosciences Inc
33.93+1.63+5.05%
VKTX
Viking Therapeutics Inc
5.92-0.11-1.82%